Smith & Nephew reported new clinical outcomes for its flagship JOURNEY II BCS knee.
In a large, multi-center retrospective patient study, new clinical evidence represented positive mid-term survivorship results on 2,059 patients with JOURNEY II BCS implants, including:
- ~1% of patients required major revision out to six years.
- No major or minor revision of any patient four years or more post-op.
- Five year revision rate that was reported as 3.6% compared to 4.1% for the cemented posterior stabilized (PS) class in the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR).
- Statistically significantly better survivorship for patients under 55 when compared to the Australian registry class average for the same age group at six years. The revision rate was 3% at 5 years for males and 3.1% for females, compared to 7% for males and 6.9% for females reported by the AOANJRR for cemented PS total knee arthroplasty procedures.
JOURNEY II launched in late 2011 and has totaled >150,000 procedures globally.
Sources: Smith & Nephew; ORTHOWORLD, Inc.